Form 4: Incyte EVP Granted 8,542 Stock Options

Incyte Corp's EVP, GM of Dermatology US, Matteo Trotta, was granted 8,542 employee stock options with an exercise price of $106.21.

Summary

• Matteo Trotta, Executive Vice President and General Manager of Dermatology US at Incyte Corp (INCY), was granted 8,542 employee stock options.
• The options have an exercise price of $106.21 per share.
• The transaction date for the grant was January 16, 2026.
• These options expire on January 15, 2036.
• The options will begin to become exercisable on January 16, 2026, with the first 25% vesting on July 15, 2026, and the remaining portion vesting monthly over the subsequent three years.
• Following this transaction, Matteo Trotta beneficially owns 8,542 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive for executive retention and alignment with shareholder interests, though it's a routine compensation event and not a major market mover.

Positives

• The grant of 8,542 employee stock options aligns the executive's interests with long-term shareholder value.
• The vesting schedule encourages retention and sustained performance over a multi-year period.

Future Outlook

The granted employee stock options will vest over a period of three years, with the first 25% vesting on July 15, 2026, and the remainder vesting monthly thereafter, indicating a long-term incentive structure for the executive.

Industry Context

This grant of stock options is a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and align executive interests with shareholder value. It reflects ongoing compensation practices within the sector for key leadership roles.

Stakeholder Impact

• Shareholders: The grant aligns the executive's long-term interests with shareholder value, potentially leading to improved performance. It also represents a potential future dilution if options are exercised, though this is standard for equity compensation.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent or benchmark for other senior roles.

Next Steps

• The options will begin to become exercisable on January 16, 2026.
• The first 25% of the options will vest on July 15, 2026.
• The remaining options will vest monthly over the subsequent three years.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Incyte Corp. It is a standard practice to incentivize management and does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Incyte Corp, INCY, Matteo Trotta, Stock Options, Executive Compensation, Form 4, SEC Filing, Dermatology, Biotechnology